Skip to main content
Premium Trial:

Request an Annual Quote

Barry Toyonaga

Premium
Traversa Therapeutics has appointed Barry Toyonaga to the position of senior vice president of business development.
 
Toyonaga will be responsible for the development and execution of global strategic partnering related to human therapeutics and high-throughput screening, the company said.
 
He previously held various positions for Johnson & Johnson, as well as its corporate venture arm, Traversa said. He has also worked in academia at institutions such as the Scripps Research Institute and the California Institute of Technology. He holds a PhD in organic chemistry from the University of Toronto.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.